Abstract 1815
Background
Leukocytosis is common in patients with malignancies and might be a negative prognostic factor in lung cancer (LC). Leukocytes are, however, a heterogenous population of blood cells. Therefore, subpopulation of leukocytes responsible for this effect should be identified. It is presumed that neutrophilia and lymphocytopenia might be a negative factor in patients with lung cancer.
Methods
Leukocyte, absolute neutrophil, lymphocyte, eosinophil, basophil and thrombocyte count were determined before beginning of treatment in patients with LC. Patients with recent bleeding, elevated CRP or treated with best-supportive care were excluded. The impact of leukocytosis, neutrophilia, lymphocytopenia, eosinophilia and basophilia on progression- free survival (PFS) was determined. Neutrophils to lymphocytes ratio (NLR) at various cut-offs were determined along with platelets to lymphocytes ratio (PLR) and their effect on PFS was assessed. Kaplan- Meier and Cox- regression statistical analysis were used.
Results
200 patients were examined in our retrospective study. Median PFS was 7.41 months. Leukocytosis and neutrophilia significantly worsened PFS in patients with LC [HR 0.5200, (95%CI 0.3684 to 0.7340), P < 0.0001 and HR 0.5556 (95%CI 0.4068 to 0.7589) P = 0.0001]. These results were confirmed in Cox- regression analysis (covariates: age, gender, stage). Lymphocytopenia, basophilia, eosinophilia and thrombocytosis had no impact on survival rates. Elevated NLR (cut- off 3.54) significantly worsened PFS in patients with LC [HR 0.6069 (95%CI 0.4475 to 0.8231), P = 0.0013] even after adjustment to covariates (age, gender, stage). Elevated NLR at lower cut-offs (2.15 and 1.77) and elevated PLR (cut-off 123) did not affect the survival rate.
Conclusions
Neutrophilia appears to be a negative prognostic factor in patients with LC. Impairment in other white blood cell lines does not affect PFS, however, significantly elevated NLR (≥ 3.54) seems to have detrimental effect on survival rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty Hospital Trencin, Department of Oncology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
603 - Mendelian Randomization Study of Alzheimer's Disease and Lung Cancer
Presenter: Huaqiang Zhou
Session: Poster Display session 1
Resources:
Abstract
4462 - Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer
Presenter: Rafael Lopez Castro
Session: Poster Display session 1
Resources:
Abstract
3957 - Pleural effusion TGF-beta is highly diagnostic and prognostic in malignant pleural mesothelioma
Presenter: Paul Stockhammer
Session: Poster Display session 1
Resources:
Abstract
3583 - Immune microenvironment modulation by p14/ARF in Malignant Pleural Mesothelioma
Presenter: Giulia Pasello
Session: Poster Display session 1
Resources:
Abstract
4255 - Tumor Treating Fields plus chemotherapy for first-line malignant pleural mesothelioma (MPM): radiological responses in the STELLAR trial
Presenter: Federica Grosso
Session: Poster Display session 1
Resources:
Abstract
1803 - Effects of Tumor Treating Fields (TTFields; 150 kHz) and Cisplatin or Pemetrexed Combination Therapy on Mesothelioma cells In Vitro and In Vivo
Presenter: Mijal Munster
Session: Poster Display session 1
Resources:
Abstract
2660 - Real world use of systemic therapy in elderly patients with malignant pleural mesothelioma (MPM)
Presenter: Susana Cedres
Session: Poster Display session 1
Resources:
Abstract
3150 - Pemetrexed/Cisplatin versus Gemcitabine/Cisplatin as first-line treatment for Egyptian patients with malignant pleural mesothelioma
Presenter: Mohamed Alorabi
Session: Poster Display session 1
Resources:
Abstract
4319 - Accuracy of pathologic evaluation for thymic epithelial tumors in an Italian reference Centre
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract
4811 - Comprehensive genomic profiling of thymic carcinoma in a sample Chinese population
Presenter: Baohui Han
Session: Poster Display session 1
Resources:
Abstract